{"id":"W2766484950","doi":"10.1016/j.jtho.2017.09.072","title":"PS04.03 LUME-Meso Phase II/III Study: Nintedanib + Pemetrexed/Cisplatin in Chemo-Naïve Patients with Malignant Pleural Mesothelioma","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Nintedanib; Medicine; Pemetrexed; Internal medicine; Oncology; Placebo; Platelet-derived growth factor receptor; Hazard ratio; Progression-free survival; Gastroenterology; Urology; Pharmacology; Cisplatin; Chemotherapy; Pathology; Confidence interval; Receptor; Growth factor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001303136,0.001320252,0.002305554,0.0004449922,0.0004677298,0.001369627,0.001094478,0.0008029565,0.0039023],"category_scores_gemma":[0.000725992,0.0006554411,0.001941445,0.0004094359,0.001049156,0.001050129,0.0004673487,0.003004323,0.001140929],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001382818,"about_ca_system_score_gemma":0.001702992,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002122528,"about_ca_topic_score_gemma":0.006722681,"domain_scores_codex":[0.9996094,0.0001845176,0.00002055697,0.00006625501,0.00002967414,0.00008949832],"domain_scores_gemma":[0.9995159,0.00006288572,0.00007018033,0.00004675023,0.00002959932,0.0002747433],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8549391,0.02474706,0.01052438,0.001009308,0.003050251,0.0001881344,0.0002552179,0.003226357,0.02079986,0.0003488089,0.005507449,0.07540404],"study_design_scores_gemma":[0.6481136,0.3164518,0.02669705,0.00006107758,0.00144657,0.0002092928,0.0001192946,0.001356249,0.001754362,0.0002952786,0.003453768,0.00004162477],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9915911,0.002672895,0.0002888928,0.0007354657,0.000236084,0.0009126269,0.00142903,0.00008690364,0.002047011],"genre_scores_gemma":[0.9877443,0.002466835,0.0007003563,0.0009184701,0.0002360944,0.001114267,0.003046211,0.00003506821,0.003738532],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0039023,"threshold_uncertainty_score":0.01305443,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02231411731401505,"score_gpt":0.404327741784861,"score_spread":0.382013624470846,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}